There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN – Research Report) and Xilio ...

This week, one Waltham biotech announced a deal to work with AbbVie that will pay out $52M upfront, while another one made ...

Shares in biotech group Xilio Therapeutics (XLO) surged over 125% today after it sealed a cancer-fighting deal with AbbVie ...

Asian markets closed mostly higher on Wednesday, with Japan's Nikkei 225 gaining 0.42%, China's Shanghai Composite Index ...

AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...

US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.

AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (NASDAQ: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with ...

NORTH CHICAGO, Ill. - Pharmaceutical (TADAWUL:2070) giant AbbVie (NYSE:ABBV), a $339 billion market cap company with a strong financial health rating according to InvestingPro, and biotech firm Xilio ...

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...

Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor ...